PT-141 for Women: Complete Guide

PT-141 (bremelanotide), sold under the brand name Vyleesi, is the only FDA-approved injectable treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike medications that target blood flow or hormones, PT-141 works through the brain’s melanocortin system — making it a fundamentally different approach to treating low sexual desire.

If you’re exploring peptide therapy options for sexual health, PT-141 stands out as one of the few peptides with full FDA approval and Phase 3 clinical trial data behind it. For a broader look at peptide options that address desire and arousal, see our full libido guide.

Key Takeaways

PT-141 is FDA-approved specifically for premenopausal women with HSDD (persistently low sexual desire causing distress)
It works through melanocortin receptors in the brain, not through hormones or blood flow
Two large Phase 3 trials (RECONNECT) showed statistically significant improvements in desire and reduced distress
The most common side effect is nausea (~40% of users), which typically improves after the first dose
It’s administered as a subcutaneous injection at least 45 minutes before anticipated sexual activity

What Is PT-141 (Bremelanotide)?
How PT-141 Works in Women
What Is HSDD?
Clinical Trial Results
Dosing and Administration
Side Effects
PT-141 vs. Flibanserin (Addyi)
Who Should Not Use PT-141
How to Get PT-141 Prescribed
FAQ
Sources

What Is PT-141 (Bremelanotide)?

PT-141 is a synthetic peptide — a short chain of amino acids — that activates melanocortin receptors in the central nervous system. It was originally derived from Melanotan II, a peptide studied for tanning, when researchers noticed it produced spontaneous arousal in test subjects [1].

The FDA approved bremelanotide (brand name Vyleesi) in June 2019 for the treatment of acquired, generalized HSDD in premenopausal women [2]. It’s part of a growing category of peptide-based treatments that target specific receptor systems rather than broadly altering hormone levels.

PT-141 is not an aphrodisiac. It doesn’t create desire from nothing. It works by reactivating pathways in the brain that regulate sexual motivation — pathways that may be underactive in women with HSDD. For a broader overview of how peptides can support sexual desire in both men and women, see our guide on peptides for libido.

How PT-141 Works in Women

Most sexual dysfunction treatments for women have targeted either hormones (testosterone, estrogen) or neurotransmitters (serotonin, dopamine). PT-141 takes a different route entirely.

It binds to melanocortin 4 receptors (MC4R) in the hypothalamus and limbic system — brain regions that regulate motivation, reward, and sexual behavior [3]. This activation triggers downstream signaling that increases dopamine and oxytocin activity in pathways associated with desire and arousal.

The mechanism matters because it explains why PT-141 works differently from other options:

It’s on-demand. You take it before anticipated activity, not daily.
It acts centrally. The effect starts in the brain, not in peripheral blood flow.
It addresses desire specifically. Not just physical arousal, but the psychological wanting.

Understanding how peptides work at the receptor level helps explain why PT-141 produces such targeted effects compared to broader hormonal treatments.

What Is HSDD?

Hypoactive sexual desire disorder is characterized by a persistent lack of sexual thoughts, fantasies, or desire for sexual activity that causes personal distress. The key word is “distress” — low desire alone isn’t a disorder. It becomes HSDD when it bothers you.

HSDD affects an estimated 10% of adult women in the United States [4]. It’s distinct from:

Normal fluctuations in desire due to stress, fatigue, or relationship issues
Medication-induced low desire (SSRIs are a common culprit)
Hormonal changes from menopause (PT-141 is currently approved only for premenopausal women)

The diagnosis requires that the low desire isn’t better explained by another medical condition, medication side effect, or relationship problem. A healthcare provider experienced in sexual medicine can help determine if HSDD is the right diagnosis.

Clinical Trial Results

PT-141’s approval was based on two identical Phase 3 randomized controlled trials known as RECONNECT (studies 301 and 302), involving over 1,200 premenopausal women with HSDD [5].

The RECONNECT Trials

Both studies ran for 24 weeks. Women self-administered 1.75 mg of bremelanotide subcutaneously as needed, at least 45 minutes before anticipated sexual activity.

Results from the combined data:

Women using PT-141 reported a statistically significant increase in desire scores on the Female Sexual Function Index (FSFI-desire domain) compared to placebo [5]
Distress related to low desire decreased significantly, measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) [5]
About 25% of women on PT-141 achieved a clinically meaningful improvement in desire, compared to 17% on placebo [5]

The effect sizes were modest but real. PT-141 won’t produce a dramatic overnight transformation for most women. But for women who’ve been struggling with persistently absent desire, even a moderate improvement can be meaningful.

Long-Term Data

A 52-week open-label extension of the RECONNECT trials followed women who continued using PT-141 over a year. No new safety signals emerged, and improvements in desire were sustained [6]. Women used the medication an average of 2-3 times per month, suggesting it filled a genuine on-demand need rather than becoming something used compulsively.

Earlier Studies

Before the Phase 3 trials, a 2006 study of 18 premenopausal women with sexual arousal disorder showed that a single intranasal dose of bremelanotide significantly increased subjective sexual arousal compared to placebo [7]. A subsequent dose-finding trial in 327 women established the 1.75 mg subcutaneous dose as the optimal balance of efficacy and tolerability [8].

Dosing and Administration

PT-141 is delivered as a subcutaneous injection in the abdomen or thigh. The FDA-approved protocol is straightforward:

Dose: 1.75 mg per injection
Timing: At least 45 minutes before anticipated sexual activity
Frequency: No more than once every 24 hours
Maximum: No more than 8 doses per month (per FDA labeling)

The injection uses a standard autoinjector, similar to an insulin pen. Most women find administration simple after the first use. If you’re new to peptide injections, the learning curve is minimal with an autoinjector compared to traditional vial-and-syringe methods.

Off-Label Compounded PT-141

Some clinics prescribe compounded bremelanotide from compounding pharmacies rather than brand-name Vyleesi. This is typically less expensive but involves reconstituting the peptide and drawing doses with an insulin syringe. The dosing is the same (1.75 mg), but the preparation requires more steps and careful measurement.

Side Effects

The most significant side effect of PT-141 is nausea, and it’s common enough that it deserves honest discussion. For a detailed breakdown of all adverse effects, see our PT-141 side effects guide.

Common Side Effects (from Phase 3 trials)

Side Effect	PT-141 Group	Placebo Group
Nausea	40.0%	1.3%
Flushing	20.3%	1.3%
Injection site reactions	13.2%	8.6%
Headache	11.3%	6.3%
Vomiting	4.8%	0.2%

Data from Vyleesi prescribing information [2].

Nausea: What to Expect

The nausea is real and deserves attention. About 4 in 10 women experience it, though there’s good news: it tends to be worst with the first dose and improves significantly with subsequent use [2].

Taking an anti-nausea medication like ondansetron 30 minutes before PT-141 can help. Eating a light meal beforehand (not too heavy, not on an empty stomach) also seems to reduce severity based on patient reports.

Blood Pressure

PT-141 causes a small, transient increase in blood pressure — typically 2-3 mmHg systolic — that resolves within 12 hours [2]. This is generally not clinically significant but means PT-141 is contraindicated in people with uncontrolled hypertension.

Skin Darkening

A small percentage of women (~1%) develop focal hyperpigmentation, particularly around the face, gums, and breasts [2]. This is related to PT-141’s melanocortin activity (the same pathway involved in tanning). The darkening may not fully reverse after stopping the medication.

For a complete look at managing these effects, check out our guide on peptide side effects broadly, and the specific PT-141 side effects page.

PT-141 vs. Flibanserin (Addyi)

PT-141 and flibanserin (Addyi) are the only two FDA-approved treatments for HSDD in premenopausal women. They work very differently:

Feature	PT-141 (Vyleesi)	Flibanserin (Addyi)
How it works	Melanocortin receptor agonist	Serotonin receptor modulator
Administration	Subcutaneous injection	Daily oral pill
Timing	On-demand (45 min before)	Taken nightly, takes 4-8 weeks
Alcohol	No restriction	Cannot drink alcohol
Most common side effect	Nausea (40%)	Dizziness, sleepiness
Onset of effect	Same day	Weeks to months

The on-demand nature of PT-141 is a major practical advantage. Many women prefer not to take a daily pill for a problem that’s situational. The alcohol restriction with flibanserin is also a significant real-world limitation.

Who Should Not Use PT-141

PT-141 is not appropriate for everyone. Contraindications include:

Uncontrolled hypertension or cardiovascular disease — due to transient blood pressure increases
Postmenopausal women — not studied or approved for this population (though off-label use occurs; see our guide to peptides for women over 40 for options that address perimenopause and postmenopause specifically)
Men — PT-141 has been studied in men for erectile dysfunction but is not FDA-approved for male use
Women on naltrexone — PT-141’s efficacy may be reduced

It’s also not indicated for low desire caused by a medical condition, medication, psychiatric disorder, or relationship problems. The diagnosis of HSDD should be made by a qualified provider.

Women considering PT-141 should discuss their full medical history with a provider who understands both peptide therapy for women and sexual medicine. The safety profile of peptides varies widely between different compounds.

How to Get PT-141 Prescribed

PT-141 requires a prescription. There are several pathways:

Your OB/GYN or primary care provider — Many are comfortable prescribing Vyleesi, though some may refer you to a sexual medicine specialist
Sexual medicine specialists — Providers with specific training in female sexual dysfunction
Telehealth clinics — Several platforms now offer remote evaluation and prescription for HSDD treatment

Brand-name Vyleesi can be expensive without insurance (over $900 per month for 8 doses). Compounded bremelanotide from a 503A or 503B compounding pharmacy is typically much more affordable, ranging from $100-300 per month depending on the pharmacy and dosing frequency.

Explore the evidence: See all 8 PT-141 studies in our research database, or browse the full peptide therapy statistics for 2026.

FAQ

How quickly does PT-141 work for women?▼

PT-141 reaches peak blood levels about 1 hour after subcutaneous injection. Most women notice effects within 45 minutes to 2 hours. Unlike daily medications, it works the same day you take it — there’s no weeks-long buildup period required [2].

Can postmenopausal women use PT-141?▼

PT-141 is FDA-approved only for premenopausal women. However, some providers prescribe it off-label for postmenopausal women. The Phase 3 trials didn’t include postmenopausal women, so the evidence base is limited for that population. Discuss with your provider.

Does PT-141 increase physical arousal or just desire?▼

PT-141 primarily targets desire — the wanting of sexual activity. However, because desire and arousal are closely linked neurologically, many women report improvements in both. The clinical trials measured desire specifically, and that’s where the statistically significant improvements were documented [5].

Can you take PT-141 with other medications?▼

PT-141 has no significant drug interactions with most common medications, including hormonal contraceptives. The exception is naltrexone (used for alcohol or opioid dependence), which may reduce PT-141’s effectiveness. Always disclose all medications to your prescriber [2].

Is PT-141 the same as Melanotan II?▼

No. PT-141 (bremelanotide) was derived from Melanotan II but is a distinct compound with a different molecular structure. Melanotan II is not FDA-approved, has a broader receptor profile, and carries different risks. PT-141 was specifically developed to target sexual function while minimizing tanning and other melanocortin effects [1].

Sources

Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. PubMed
Vyleesi (bremelanotide injection) prescribing information. AMAG Pharmaceuticals, Inc; 2019. FDA Label
Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci. 2004;101(27):10201-10204. PubMed
Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970-978. PubMed
Kingsberg SA, Clayton AH, Pfaus JG, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. PMC
Simon JA, Kingsberg SA, Portman D, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909-917. PMC
Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638. PubMed
Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325-337. PubMed